ABSTRACT
INTRODUCTION
Ayurvedic medicine is a traditional system native to India and has been positioned as mainstream system of medicine since thousands of years. Globally, this system of medicine gained significance as an alternative and complementary medicine 1, 2 . This system uses natural plant based medicines and minerals including sulfur, arsenic, lead, copper and gold are often added to formulations with the belief that these metals are essential components of vital molecules within the human body Indian Ayurvedic system and herbal medicines have attracted the global attention due to their slow and explicit cure (Anand Prem Rajan) . Approximately 80% of India's 1 billion population use ayurveda 4, 5 . This developing interest and usage raised up safety concerns about Ayurveda. Recent studies conducted by United States on this system of medicine found about 20% of ayurvedic treatments are containing toxic levels of heavy metals such as lead, mercury and arsenic 6 . Rasashastra, an intergral part of Ayurveda, deals with drugs of mineral origin comprehensively. In traditional Ayurvedic medicine as part of Rasa Shastra, practioners add minerals to plants/animal origin drugs and claim that such medicines are safe, when they are properly purified and detoxified. According to 'The Ayurvedic Formulary of India' mercury and lead are the most widely used heavy metals. As these metals are potent nephrotoxic, hepatotoxic, neurotoxic and hematotoxic agents 6, 7 . The toxicokinetics of these metals in ayurvedic preparations is geared up. Since there are no clear standards and recommendations are defined for metals contamination in ayurvedic preparations. In adequate scientific studies and clinical trials of many ayurvedic products lead to such circumstances 6 . This study was aimed to investigate toxicokinetic parameters, to detect and estimate mercury accumulation in various organs on a 28 days intake of Shila sindur, a herbo-mineral preparation composed of mercury, sulphur and arsenic disulfide (realgar) along with aloe vera. Shila sindur is indicated for all types of skin disorders, skin diseases associated with itching, skin conditioning and other diseases of infectious origin like fever, abscess, gonorrhea, cardio protection and neuro protection 8 .
MATERIALS AND METHODS

Reagents and chemicals
Shila sindur was procured from the local market. Sodium Carboxy Methyl Cellulose, haemotoxylin, eosin, mercuric chloride, 2-mercaptoethanol and HPLC grade methanol were procured from SD fine chem., Mumbai. All reagents and chemicals used were analytical grade.
Animals
Male adult Wistar albino rats age of 6-7 weeks, weighing between 150 to 200g, were used in the study. They were procured from the Mahaveera enterprises (Reg no.146/1999 CPCSEA) Hyderabad, Andhra Pradesh. The animals were housed at CPCSEA Approved (Reg.no.1047/ac/07 CPCSEA) animal house of Vaagdevi college of Pharmacy. They were maintained under standard laboratory conditions at an ambient temperature of 25 ± 2°C and 50 ± 15% relative humidity, with a 12-h light/12-h dark cycle. Rats were fed with a commercial pellet diet (Hindustan lever Pvt. Ltd. Bombay, India.) and water ad libitum. They were fasted for 18 h prior to the experiment and during the experiment; the food and water were withdrawn. The animal experiments were performed after prior approval of the study protocol by 
Toxicokinetic studies
Toxicokinetic studies were conducted as per OECD guideline 417 9 . The animals were grouped into 3 groups of 6 animals each. The doses were set as 50 mg/kg (low), 300 mg/kg (medium) and 1000 mg/kg (High). Shila sindur was administered orally (suspension with 0.1% Sodium CMC) to overnight fasted rats (OECD 417). Blood samples were taken at 1hr, 2hr, 4hr, 6hr, 12hr, 24hr and 48hr by retro-orbital puncture.
Tissue Distribution Studies
Tissue distribution studies guidelines were adopted from OECD guideline 417 9 . Animals were divided into six groups based on the dose and frequency of administration of drug i.e., High/repeated doses, High/single dose, Medium/repeated doses, Medium/single dose, Low/repeated doses, Low/single dose). In each group 6 animals were taken. In repeated doses groups, the shila sindur was administered for 28 days. After 24 hrs (for single dose) and 28 th day (for repeated doses), the animals were sacrificed. Liver, lungs, kidneys, brain and spleen were collected and then weighed for wet weight and homogenized in phosphate buffer saline (PBS) of pH 7.4. The tissue homogenates were centrifuged at approximately 4000 rpm for 20 min and stored at -20 0 C until analysis.
Clinical Bio-Chemistry Parameters
Clinical biochemical parameters like hematological parameters assessed by using Erba Heamo Lab-8 Heamaolog analyser ( US Tech Inc, Washington MD, USA); liver function parameters i.e., SGOT and SGPT; Kidney function by assessing Serum Creatinine were conducted by using respective diagnostic kits (Crest Biosystems).
Histopathology
The rats were sacrificed by cervical dislocation. Complete necropsies were carried out on all animals. Tissues were preserved in 10% neutral buffered formalin. The tissues examined were brain, lungs, liver, spleen and kidney. Tissues were subjected to microscopic examination by embedding in paraffin wax, sectioned at five micrometers thickness by using Microtome (Rofin, Switzerland) and stained with haemotoxylin and eosin. Scanning Electron Microscopy (SEM) images were obtained for all the tissues (SEM-Joel, USA) to observe histopathology at various doses.
Analysis
The blood samples were analyzed using HPLC-ICP-MS. The kinetic parameters were estimated using Kinetica (version 5.0)
HPLC -ICP MS method validation for the presence of mercury
1. Equipment: Total mercury concentrations were determined using a Perkin Elmer SCIEX Elan DRC-e ICPMS (Table 1) . Mercury species were determined using a Perkin Elmer series 200 HPLC pump with a Perkin-Elmer 3_mC8 (33mm×3mm) column coupled to a Perkin Elmer Sciex Elan 6000 ICPMS ( Table  2) 
Standards:
A stock solution (1000mg/l) of mercury (II) was prepared by dissolving the appropriate amount of mercuric chloride in de-ionized water. Stock solution was stored in airtight bottle and refrigerated. Working standards [(10ng/ml to 3 µg/ml) and (5, 10, 30, 50,100µg/ml)} were prepared daily from the stock solution by serial dilution using extracting solutions.
Reagents:
All reagents were analytical reagent grade and used without further purification. A 2-mercaptoethanol solution was prepared containing 0.5% (v/v) 2-mercaptoethanol in 5% (v/v) methanol and used as the extracting reagent and mobile phase for HPLC-ICPMS work.
Measurement of Hg concentration in Rat tissues and sediments by 2-mercaptoethanol extraction:
Freeze-dried samples (0.2 g) were weighed into 55 ml polytetrafluroacetate (PTFE) digestion vessels (CEM, USA) with 5ml and 2.5 ml of 0.5% (v/v) 2-mercaptoethanol for rat tissues and sediment samples respectively. The vessels were heated in a microwave oven at 120 0 C for 15 min. The extracts were transferred to acid washed 10 ml polypropylene centrifuge tubes and centrifuged in an Eppendorf centrifuge 5804 for 20 min at 3000 rpm. For sediment samples, after the supernatant was separated, the extraction was repeated and extracts combined.
HPLC-ICP-MS:
All supernatants were filtered through Acrodisc LC 13-mm Syringe filters with 0.2_mPVDF membranes before analysis. Aliquots of extracts (100µl) were injected onto the HPLC-ICP-MS (Table 2) . External calibration using the standards 0-100µg/l was used. The chromatography package Turbochrom Navigator (Perkin Elmer, Australia) was used to quantify mercury species by peak area. 
RESULTS AND DISCUSSION
A. Blood Hg profile at various doses: All values expressed as Mean ± SD, (n=4); *p<0.05 significant, **p<0.01 highly significant, ***p<0.001 very highly significant. Statistical Comparision was performed by using ANOVA coupled with Dunnet's multiple comparision test. 
B. Toxicokinetic parameters
C. Tissue distribution studies
C. Ratio of tissue -blood concentrations
Concentration of Mercury in Various Organs
Liver function tests: SGOT and SGPT estimation
Kidney function test: serum creatinine estimation
DISCUSSION
Repeated dose toxicity studies categorically suggest that with increasing doses there were significant changes taken place in the clinical/ biochemical parameters evaluated. Though the changes are not intense, but changes occurred in the complete blood picture were significant at higher doses. The elevated serum creatinine levels indicating an extensive damage to the kidney at higher doses. The glomeruli in the kidneys are those which were extensively damaged and inflammation mediated necrotic tissues were mainly seen in the medium and high dose study groups. A significant damage to the liver is indicated by the elevations in the SGPT and SGOT levels. The changes in the clinical/ biochemical parameters were strongly supported by the histopathological studies. There was also level II (medium) damage in lungs and liver in higher repetitive doses. There was a strong positive correlation between the clinical parameters, histopathological studies and the tissue concentrations in the study groups which is pivotal for these present investigations. Mercury concentrations in the kidney are very high followed by the liver and lungs. Some accumulation of mercury is also observed in spleen and the least content observed in brain. There was 15 to 20 fold increase in the kidney mercury concentrations in high dose compared to low dose groups. Tissue to blood concentrations is also high, suggesting a strong association and high affinity binding that led to damage of glomeruli leading to elevation in creatinine levels. In liver there was 5 fold increase in mercury levels between the low dose and high dose groups and hence necrosis in the hepatocytes and subsequent elevation in SGPT and SGOT levels.
B A C D
There was dose dependent increase in the plasma concentrations. From the toxicokinetic parameters, Plasma clearance (CL) was extremely low with high half life (T 1/2 ). This strongly correlates with the high plasma protein binding/affinity of mercury. Increase in AUC and V d was also observed with increasing doses. But it is quite evident from the study that plasma concentrations and subsequent PK analysis doesn't supinely speak about the toxicity of mercury as evident from the tissue concentrations even at low doses. Saturation kinetics of the mercury at high dose needs further investigations.
CONCLUSION
Above investigations categorically conclude that low single dose or even low repeated dose of mercury could be safe and may not lead to accumulation in the tissues especially in kidney -the target organ prone to damage. Medium dose administration needs stringent monitoring of the clinical/biochemical parameters for optimization of the dose. At this dose the administration of the drug or its continuation is at the discretion of the medical practitioner. High single dose and high repeated doses have showed very deleterious effects, further continuation may lead to severe nephrotoxicity, thus shila sindur at higher doses are not advisable for administration. Therefore, the process of purification and preparation of the product-shila sindur need to be improved.
